Arrowhead Pharmaceuticals (ARWR) Cash from Investing Activities (2011 - 2026)

Arrowhead Pharmaceuticals' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$894.3 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 112.82% year-over-year to -$894.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$704.0 million (down 25.88% YoY) and the FY2025 annual result came in at -$129.3 million, up 69.22% from the prior year.
• Cash from Investing Activities was -$894.3 million for Q1 2026 at Arrowhead Pharmaceuticals, down from -$23.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $141.4 million in Q2 2025 and bottomed at -$894.3 million in Q1 2026.
• A 5-year average of -$90.3 million and a median of -$9.9 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities slumped 830.68% — and 2025, when it soared 1934.68%.
• Arrowhead Pharmaceuticals' Cash from Investing Activities stood at -$80.7 million in 2022, then soared by 180.35% to $64.8 million in 2023, then climbed by 18.62% to $76.9 million in 2024, then sank by 130.87% to -$23.7 million in 2025, then plunged by 3666.67% to -$894.3 million in 2026.
• Business Quant data shows ARWR's Cash from Investing Activities at -$894.3 million in Q1 2026, -$23.7 million in Q4 2025, and $72.6 million in Q3 2025.